|
1
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaught D, Brantley-Sieders DM and Chen J:
Eph receptors in breast cancer: Roles in tumor promotion and tumor
suppression. Breast Cancer Res. 10:2172008. View Article : Google Scholar
|
|
3
|
Hirai H, Maru Y, Hagiwara K, Nishida J and
Takaku F: A novel putative tyrosine kinase receptor encoded by the
eph gene. Science. 238:1717–1720. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dodelet VC and Pasquale EB: Eph receptors
and ephrin ligands: Embryogenesis to tumorigenesis. Oncogene.
19:5614–5619. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhuang G, Brantley-Sieders DM, Vaught D,
Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen
J: Elevation of receptor tyrosine kinase EphA2 mediates resistance
to trastu-zumab therapy. Cancer Res. 70:299–308. 2010. View Article : Google Scholar
|
|
6
|
Brantley-Sieders DM, Jiang A, Sarma K,
Badu-Nkansah A, Walter DL, Shyr Y and Chen J: Eph/ephrin profiling
in human breast cancer reveals significant associations between
expression level and clinical outcome. PLoS One. 6:e244262011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu M, Miller KD, Gokmen-Polar Y, Jeng MH
and Kinch MS: EphA2 overexpression decreases estrogen dependence
and tamoxifen sensitivity. Cancer Res. 63:3425–3429.
2003.PubMed/NCBI
|
|
8
|
Wu Q, Suo Z, Risberg B, Karlsson MG,
Villman K and Nesland JM: Expression of Ephb2 and Ephb4 in breast
carcinoma. Pathol Oncol Res. 10:26–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zelinski DP, Zantek ND, Stewart JC,
Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis
of mammary epithelial cells. Cancer Res. 61:2301–2306.
2001.PubMed/NCBI
|
|
10
|
Brantley-Sieders DM: Clinical relevance of
Ephs and ephrins in cancer: Lessons from breast, colorectal, and
lung cancer profiling. Semin Cell Dev Biol. 23:102–108. 2012.
View Article : Google Scholar :
|
|
11
|
Kumar SR, Singh J, Xia G, Krasnoperov V,
Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, et al:
Receptor tyrosine kinase EphB4 is a survival factor in breast
cancer. Am J Pathol. 169:279–293. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Noren NK, Foos G, Hauser CA and Pasquale
EB: The EphB4 receptor suppresses breast cancer cell tumorigenicity
through an Abl-Crk pathway. Nat Cell Biol. 8:815–825. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berclaz G, Flütsch B, Altermatt HJ,
Rohrbach V, Djonov V, Ziemiecki A, Dreher E and Andres AC: Loss of
EphB4 receptor tyrosine kinase protein expression during
carcinogenesis of the human breast. Oncol Rep. 9:985–989.
2002.PubMed/NCBI
|
|
14
|
Nikolova Z, Djonov V, Zuercher G, Andres
AC and Ziemiecki A: Cell-type specific and estrogen dependent
expression of the receptor tyrosine kinase EphB4 and its ligand
ephrin-B2 during mammary gland morphogenesis. J Cell Sci.
111:2741–2751. 1998.PubMed/NCBI
|
|
15
|
Mäkinen T, Adams RH, Bailey J, Lu Q,
Ziemiecki A, Alitalo K, Klein R and Wilkinson GA: PDZ interaction
site in ephrinB2 is required for the remodeling of lymphatic
vasculature. Genes Dev. 19:397–410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salvucci O, Maric D, Economopoulou M,
Sakakibara S, Merlin S, Follenzi A and Tosato G: EphrinB reverse
signaling contributes to endothelial and mural cell assembly into
vascular structures. Blood. 114:1707–1716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Follenzi A and Naldini L: Generation of
HIV-1 derived lentiviral vectors. Methods Enzymol. 346:454–465.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Falivelli G, Lisabeth EM, Rubio de la
Torre E, Perez-Tenorio G, Tosato G, Salvucci O and Pasquale EB:
Attenuation of eph receptor kinase activation in cancer cells by
coexpressed ephrin ligands. PLoS One. 8:e814452013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rutqvist LE and Johansson H: Long-term
follow-up of the Stockholm randomized trials of postoperative
radiation therapy versus adjuvant chemotherapy among 'high risk'
pre- and postmenopausal breast cancer patients. Acta Oncol.
45:517–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Veenstra C, Pérez-Tenorio G, Stelling A,
Karlsson E, Mirwani SM, Nordensköljd B and Fornander T: Met and its
ligand HGF are associated with clinical outcome in breast cancer.
Oncotarget. 7:37145–37159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Husa AM, Magić Ž, Larsson M, Fornander T
and Pérez-Tenorio G: EPH/ephrin profile and EPHB2 expression
predicts patient survival in breast cancer. Oncotarget.
7:21362–21380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pawitan Y, Bjöhle J, Amler L, Borg AL,
Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene
expression profiling spares early breast cancer patients from
adjuvant therapy: Derived and validated in two population-based
cohorts. Breast Cancer Res. 7:R953–R964. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruan SQ, Wang SW, Wang ZH and Zhang SZ:
Regulation of HRG-β1-induced proliferation, migration and invasion
of MCF-7 cells by upregulation of GPR30 expression. Mol Med Rep.
6:131–138. 2012.PubMed/NCBI
|
|
25
|
Mezi S, Todi L, Orsi E, Angeloni A and
Mancini P: Involvement of the Src-cortactin pathway in migration
induced by IGF-1 and EGF in human breast cancer cells. Int J Oncol.
41:2128–2138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rutkowski R, Mertens-Walker I, Lisle JE,
Herington AC and Stephenson SA: Evidence for a dual function of
EphB4 as tumor promoter and suppressor regulated by the absence or
presence of the ephrin-B2 ligand. Int J Cancer. 131:E614–E624.
2012. View Article : Google Scholar
|
|
27
|
Alam SM, Fujimoto J, Jahan I, Sato E and
Tamaya T: Coexpression of EphB4 and ephrinB2 in tumor advancement
of uterine cervical cancers. Gynecol Oncol. 114:84–88. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan
F, Bucana CD and Ellis LM: Coexpression of ephrin-Bs and their
receptors in colon carcinoma. Cancer. 94:934–939. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang XX, Brodeur GM, Campling BG and
Ikegaki N: Coexpression of transcripts encoding EPHB receptor
protein tyrosine kinases and their ephrin-B ligands in human small
cell lung carcinoma. Clin Cancer Res. 5:455–460. 1999.PubMed/NCBI
|
|
30
|
Noberini R, Rubio de la Torre E and
Pasquale EB: Profiling Eph receptor expression in cells and
tissues: A targeted mass spectrometry approach. Cell Adh Migr.
6:102–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Foo SS, Turner CJ, Adams S, Compagni A,
Aubyn D, Kogata N, Lindblom P, Shani M, Zicha D and Adams RH:
Ephrin-B2 controls cell motility and adhesion during
blood-vessel-wall assembly. Cell. 124:161–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bochenek ML, Dickinson S, Astin JW, Adams
RH and Nobes CD: Ephrin-B2 regulates endothelial cell morphology
and motility independently of Eph-receptor binding. J Cell Sci.
123:1235–1246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guijarro-Muñoz I, Sánchez A,
Martínez-Martínez E, García JM, Salas C, Provencio M,
Alvarez-Vallina L and Sanz L: Gene expression profiling identifies
EPHB4 as a potential predictive biomarker in colorectal cancer
patients treated with bevacizumab. Med Oncol. 30:5722013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tu Y, He S, Fu J, Li G, Xu R, Lu H and
Deng J: Expression of EphrinB2 and EphB4 in glioma tissues
correlated to the progression of glioma and the prognosis of
glioblastoma patients. Clin Transl Oncol. 14:214–220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ,
et al: The somatic mutation profiles of 2,433 breast cancers
refines their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
